NASDAQ:CTMX CytomX Therapeutics (CTMX) Stock Price, News & Analysis $1.50 +0.08 (+5.63%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.43▼$1.5150-Day Range$1.21▼$1.9252-Week Range$1.04▼$5.85Volume572,223 shsAverage Volume3.51 million shsMarket Capitalization$116.88 millionP/E Ratio7.50Dividend YieldN/APrice Target$5.77 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get CytomX Therapeutics alerts: Email Address CytomX Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside284.8% Upside$5.77 Price TargetShort InterestHealthy9.93% of Shares Sold ShortDividend StrengthN/ASustainability-0.74Upright™ Environmental ScoreNews Sentiment1.25Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.14) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.81 out of 5 starsMedical Sector38th out of 936 stocksPharmaceutical Preparations Industry12th out of 436 stocks 4.3 Analyst's Opinion Consensus RatingCytomX Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCytomX Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CytomX Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.93% of the outstanding shares of CytomX Therapeutics have been sold short.Short Interest Ratio / Days to CoverCytomX Therapeutics has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CytomX Therapeutics has recently decreased by 3.85%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCytomX Therapeutics does not currently pay a dividend.Dividend GrowthCytomX Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytomX Therapeutics has received a 74.21% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health", "Basic medical research services", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for CytomX Therapeutics is -0.74. Previous Next 4.0 News and Social Media Coverage News SentimentCytomX Therapeutics has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for CytomX Therapeutics this week, compared to 2 articles on an average week.Search Interest7 people have searched for CTMX on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.MarketBeat Follows2 people have added CytomX Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CytomX Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of CytomX Therapeutics is held by insiders.Percentage Held by Institutions67.77% of the stock of CytomX Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CytomX Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for CytomX Therapeutics are expected to decrease in the coming year, from ($0.14) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CytomX Therapeutics is 7.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of CytomX Therapeutics is 7.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Read more about CytomX Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About CytomX Therapeutics Stock (NASDAQ:CTMX)CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Read More CTMX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CTMX Stock News HeadlinesJuly 26 at 1:12 AM | americanbankingnews.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $5.77 Average PT from BrokeragesJuly 25 at 10:03 AM | msn.comCytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now?July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 22, 2024 | finance.yahoo.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 47% of the companyJune 18, 2024 | globenewswire.comCytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceJune 17, 2024 | globenewswire.comCytomX Therapeutics Promotes Chris Ogden to Chief Financial OfficerMay 29, 2024 | investorplace.comNo Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.May 29, 2024 | investorplace.comNo Memes, Ma'am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.July 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 29, 2024 | msn.comPiper Sandler Upgrades CytomX Therapeutics (CTMX)May 22, 2024 | globenewswire.comCytomX Therapeutics to Present at the Jefferies Global Healthcare ConferenceMay 16, 2024 | globenewswire.comCytomX Therapeutics Announces New Employment Inducement GrantsMay 11, 2024 | wsj.comCytomX Therapeutics Inc.May 9, 2024 | finance.yahoo.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | markets.businessinsider.comCautious Hold on CytomX Therapeutics Pending Comprehensive CX-904 Drug DataMay 9, 2024 | msn.comCytomX slides after early data for Amgen-partnered cancer drugMay 9, 2024 | markets.businessinsider.comAnalysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic CancerMay 9, 2024 | investorplace.comWhy Is CytomX (CTMX) Stock Down 43% Today?See More Headlines Receive CTMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CytomX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTMX CUSIPN/A CIK1501989 Webwww.cytomx.com Phone(605) 515-3185Fax650-351-0353Employees170Year FoundedN/APrice Target and Rating Average Stock Price Target$5.77 High Stock Price Target$8.00 Low Stock Price Target$3.50 Potential Upside/Downside+284.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.20 Trailing P/E Ratio7.50 Forward P/E RatioN/A P/E GrowthN/ANet Income$-570,000.00 Net Margins13.87% Pretax Margin17.18% Return on Equity-30.70% Return on Assets8.10% Debt Debt-to-Equity RatioN/A Current Ratio1.16 Quick Ratio1.16 Sales & Book Value Annual Sales$101.21 million Price / Sales1.15 Cash FlowN/A Price / Cash FlowN/A Book Value($0.71) per share Price / Book-2.11Miscellaneous Outstanding Shares77,920,000Free Float72,465,000Market Cap$116.88 million OptionableOptionable Beta1.06 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Sean A. McCarthy DPHIL (Age 57)Chairman & CEO Comp: $1.03MKey CompetitorsSelecta BiosciencesNASDAQ:SELBDURECTNASDAQ:DRRXMEI PharmaNASDAQ:MEIPRedHill BiopharmaNASDAQ:RDHLConcert PharmaceuticalsNASDAQ:CNCEView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Bought 833,825 shares on 7/18/2024Ownership: 1.589%Congress Park Capital LLCBought 919,420 shares on 7/12/2024Ownership: 1.480%Tidal Investments LLCSold 18,006 shares on 5/17/2024Ownership: 0.370%Jacobs Levy Equity Management Inc.Sold 261,486 shares on 5/16/2024Ownership: 0.680%Acadian Asset Management LLCBought 44,640 shares on 5/10/2024Ownership: 3.949%View All Insider TransactionsView All Institutional Transactions CTMX Stock Analysis - Frequently Asked Questions How have CTMX shares performed this year? CytomX Therapeutics' stock was trading at $1.55 at the beginning of the year. Since then, CTMX shares have decreased by 3.2% and is now trading at $1.50. View the best growth stocks for 2024 here. How were CytomX Therapeutics' earnings last quarter? CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its earnings results on Wednesday, May, 8th. The biotechnology company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.23. The biotechnology company earned $41.46 million during the quarter, compared to analyst estimates of $23.40 million. CytomX Therapeutics had a net margin of 13.87% and a negative trailing twelve-month return on equity of 30.70%. What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO? 12 employees have rated CytomX Therapeutics Chief Executive Officer Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among the company's employees. 80.0% of employees surveyed would recommend working at CytomX Therapeutics to a friend. Who are CytomX Therapeutics' major shareholders? Top institutional shareholders of CytomX Therapeutics include Assenagon Asset Management S.A. (1.59%) and Congress Park Capital LLC (1.48%). Insiders that own company stock include Sean A Mccarthy, Marcia Belvin, Lloyd A Rowland, Jeffrey B Landau, Christopher Ogden, Amy C Peterson, Carlos Campoy and Elaine V Jones. View institutional ownership trends. How do I buy shares of CytomX Therapeutics? Shares of CTMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CytomX Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE) and SCYNEXIS (SCYX). This page (NASDAQ:CTMX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
